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Sangeet Lal1 and Corey Raffel1
1Department of Neurological Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158, USAModified measles virus (MV) has effective oncolytic activity
preclinically and is currently being investigated in clinical
trials for various types of cancer. We investigated the use
of cystine knot proteins (CKPs) to direct MV activity. CKPs
are short polypeptides that bind their targets with high affin-
ity. We used a CKP that binds avb3, avb5, and a5b1 integ-
rins with single-digit nanomolar affinity to retarget MV to
the integrins (MV-CKPint). MV-CKPint infected, replicated
in, and killed human glioblastoma, medulloblastoma, diffuse
intrinsic pontine glioma (DIPG), and melanoma cancer cells
in vitro, all of which express the target integrins. MV-CKPint
activity was competitively blocked by echistatin, an integrin
binding peptide. When the CKP was cleaved from the
viral H protein at an included protease site, virus activity
was abrogated. When delivered intravenously (i.v.), the retar-
geted virus reached a subcutaneous glioblastoma tumor bed
and produced cytopathic effects similar to that shown by in-
tratumoral injection of the virus. Because these target integ-
rins are overexpressed by tumor vascular endothelium,
MV-CKPint may allow for effective therapy with i.v. injection.
These results indicate for the first time that CKPs can be used
to retarget MV for a receptor of choice. In addition, MV-
CKPint provides proof of principle for the use of a CKP of
interest to retarget any enveloped virus for both oncolytic
and gene therapy purposes.Received 24 March 2017; accepted 26 September 2017;
https://doi.org/10.1016/j.omto.2017.09.005.
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E-mail: corey.raffel@ucsf.eduINTRODUCTION
Standard therapy for malignant brain tumors has failed to achieve
meaningful prolongation of survival. For example, combined radia-
tion therapy and chemotherapy with temozolomide, the current stan-
dard of care for glioblastoma multiforme (GBM), has been shown to
prolong overall survival only 2.5 months over irradiation alone, and
most patients still progress to death caused by the tumor.1 While
the success of treating the most common pediatric malignant brain
tumor, medulloblastoma, is better, with 5-year survival rates of 70%
or more, most children are left with significant cognitive and endo-
crine deficits after therapy that result in poor quality of life.2,3 Clearly,
new strategies that have a greater impact on survival and that have
fewer long-term side effects are needed for the treatment of malignant
brain tumors in adults and children.
The use of replication-competent oncolytic viruses (OVs) as anti-
cancer agents has promise as a tumor-specific therapy. In our lab-This is an open access article under the CC BY-NCoratory, we have been investigating a vaccine strain of measles
virus (MV) as a potential therapy for pediatric brain tumors. We
have demonstrated efficacy in the treatment of intraparenchymal
and cerebrospinal fluid (CSF)-disseminated murine xenograft
models of medulloblastoma and in the treatment of intraparenchy-
mal atypical teratoid/rhabdoid tumor.4–6 Similarly, MV has proven
efficacious in the treatment of a murine xenograft model of
intracerebral GBM.7 Animal safety studies have demonstrated no
evidence of toxicity from injection of MV into the brain or CSF,
leading to open phase 1 trials for the treatment of recurrent
intracerebral GBM and recurrent intraparenchymal and/or
CSF-disseminated medulloblastoma and atypical teratoid/rhabdoid
tumor (AT/RT).8,9
One of the advantages of MV is the ease with which the virus can be
retargeted to cell surface antigens of choice. The production of such
viruses has proven laborious, as the receptor-binding motif used is
often a single-chain antibody. An alternative receptor-binding motif
may be cystine knot proteins (CKPs). These small peptides of 20–50
amino acids containing two or three disulfide bonds bind to a specific
target with single-digit nanomolar to picomolar binding coeffi-
cients.10 In this paper, we manufacture a retargeted MV that uses a
CKP that binds avb3, avb5, and a5b1 integrins with single-digit
nanomolar affinity to retarget MV to the integrins (MV-CKPint).
The CKP used expresses the integrin-binding motif arginine-
glycine-aspartic acid (RGD) in the solvent-exposed loop of the pep-
tide.11 This CKP was specifically selected for restricted binding to
the tumor-specific integrins avb3, avb5, and a5b1, and binds to these
integrins with single-digit nanomolar affinity. We demonstrate that
MV can be retargeted to these integrins by the CKP and that MV-
CKPint binds to, replicates in, and kills tumor cells in vitro. Proteo-
lytic removal of CKP abrogates infection and cell killing, indicating
that specific binding of the CKP motif mediates cellular entry of the
virus. In addition, we show that this retargeted virus infects tumor
cells in a murine xenograft model when delivered by intravascular in-
jection. These results suggest the possible use of any CKP of interest toMolecular Therapy: Oncolytics Vol. 7 December 2017 ª 2017 57
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Structure and Function of MV-CKPint
(A) Genomic organization of the modified MV-CKPint vi-
rus. The integrin-binding cystine knot protein (CKP) motif
is cloned at the C terminus of the double mutant H protein
that cannot bind to its normal receptors, CD46 and SLAM
(mutations are shown with a star symbol). A 6xHis tag
expressed at the terminal carboxyl end of the recombinant
H protein allows virus preparation using a-His Vero cells.
(B) The infection ability of the recombinant virus was
tested on a-His Vero cells and human medulloblastoma
(D283-med) cells. When infected at an MOI of 1, both cell
lines show the formation of green florescent multinucle-
ated syncytia. Scale bar, 50 mm.
Molecular Therapy: Oncolyticsretarget MV and, indeed, suggest that CKPs can be used to retarget
any enveloped virus.
RESULTS
The Integrin-Binding CKP Motif Is Expressed at the C Terminus
of the H Protein
MV normally binds to its receptors via the H protein. The H protein
encoded by the viral genome used to manufacture MV-CKPint has
two mutations (Y481A and R533A) that eliminate binding to CD46
and SLAM, the normal MV receptors. The integrin-binding CKP
was expressed at the carboxyl end of the H protein, resulting in its
exposure on the surface of the virus (Figure 1A). The functionality
of the MV-CKPint was verified by infecting anti-His (aHis)-Vero
cells. These modified cells express membrane-bound single-chain
antibody for hexahistidine and hence facilitate viral entry through
binding of the 6xHis tag at the C terminus of the MV-CKPint virus
(Figure 1B). We also tested this virus on the D283-medulloblastoma
cell line (Figure 1B). The MV-CKPint virus successfully infected
aHis-Vero and D283-med cells, and large syncytia fluorescing with
the GFP were formed in both cell lines. In D283-med cells, GFP
florescence is clearly visible in the perinuclear space, which is typical
for MV. This finding indicates that adding the integrin-binding
CKP to the H protein is functional and allows for infection, and repli-
cation of, the virus.
MV-CKPint Infects and Produces Cytopathic Effect in Cells of
Different Tumor Types
To investigate CKP-mediated cellular infection, we analyzed tumor
cell lines of different origin, glioblastoma, diffuse intrinsic pontine
glioma (DIPG), medulloblastoma, and melanoma for expression of
target integrins. Flow cytometry confirmed that all tested cell lines ex-
pressed avb3, avb5, and a5b1 integrins on the membrane (Figure 2,
right panel). The percentages of cells positive for each integrin dimers58 Molecular Therapy: Oncolytics Vol. 7 December 2017are shown in parentheses. The expression of the
GFP protein in the MV-CKPint virus was used
as a marker of infection. After infection with
the virus, cell lines of all tested tumor types
showed multiple green florescent syncytia (Fig-
ure 2, left panel). Syncytia formation becamevisible as early as 48 hr post-infection. The formation of syncytia
indicates that MV-CKPint infects and grows in cells expressing target
integrins.
MV-CKPint Replicates in andKills Cells of Different Tumor Types
Human glioblastoma, DIPG, medulloblastoma and melanoma cells,
and Vero cells were infected with increasing MOIs of MV-CKPint
virus. The virus killed all these cell types in a dose-dependent
manner (Figures 3A–3E). When infected at an MOI of 1, 75% glio-
blastoma cells and 60% medulloblastoma cells died after 96 hr,
whereas 53% of melanoma cells were killed by the virus in that
period. Because this virus targets three integrin dimers, a precise cor-
relation between a particular integrin expression and cell killing by
MV-CKPint could not be established. In a separate set of experi-
ments, the oncolytic efficacy of the retargeted MV-CKPint virus
was compared side by side with the parental Edmonston strain of
the virus (MV-GFP). When infected at an MOI of 1, the killing of
all these cell types by both viruses was comparable and statistically
significant compared to the untreated control at 96 hr post-infection
(Figure 3F).
To determine the replication competency of MV-CKPint, we
infected human glioblastoma, melanoma, and Vero cells with
0.2 MOI of the virus. Because MV-CKPint expresses GFP as a
marker, the replication of the virus in live infected cells was
measured in a time course by flow cytometry. The intensity of
GFP florescence in all these cell lines increased over time, and the
percentages of cells positive for GFP expression are shown in paren-
theses for each time point (Figure 4A). The GFP fluorescence in un-
treated control cells was used as a baseline. As a second approach,
the titer of cell-associated virus was quantified daily after infection
of U87 and MDAMB-435 cells with 0.2 MOI of the virus. As shown
in Figure 4B, the titer of infectious virus particles in these cells
Figure 2. MV-CKPint Virus Infects Cells of Different Tumor Types
Human glioblastoma, DIPG, melanoma and medulloblastoma cells, and Vero cells (monkey kidney) were infected with the modified virus at an MOI of 1 for 3 hr at 37C. The
infection of cells and formation of syncytia were monitored by GFP florescence. Scale bar, 50 mm. The expression of target integrins of CKP on live cells was determined by
flow cytometry after incubation with monoclonal antibody for each integrin dimer. The percentages of cells expressing each dimer are shown in parentheses (% +ve cells). The
IgG isotype control antibody (IgG) was used as a reference for staining.
www.moleculartherapy.orgincreased gradually over the period of 4 days post-infection, demon-
strating replication of the virus in these cell types. The replication ef-
ficiency of the retargeted MV-CKPint virus was compared with that
of the parental Edmonston virus strain (MV-GFP). Human U87
glioblastoma cells were infected in parallel with both viruses at an
MOI of 0.1, and the titer of cell-associated virus was quantified daily
on Vero cells for 4 days post-infection. After 24 hr of infection, the
titer of MV-GFP was higher with formation of many florescent syn-
cytia, whereas no syncytia were observed and the titer of infectious
particles was significantly lower for MV-CKPint virus (Figure 4C).
Nevertheless, the titer of the infectious MV-CKPint virus particles
increased over time and rose slightly higher than that of MV-GFP
at 72 and 96 hr time points. This suggests that the initial replication
and intracellular assembly of the retargeted MV-CKPint virus in U87
glioblastoma cells is slower than the parental MV, but the virus effi-
ciently replicates and the titer of infectious virus increases over time.These results show that the MV-CKPint virus efficiently replicates in
and kills tumor cells in vitro.
Infection of MV-CKPint Is Dependent on the Integrin Binding of
the CKP
If the integrin-binding motif of CKP is responsible for cell binding
and entry of the retargeted virus, the presence of a soluble antagonist
of target integrins should inhibit the interaction of virus with cells,
thereby blocking infection. To verify the requirement for integrin
binding, we assessed infection and cell killing by MV-CKPint in the
presence of echistatin, a potent competitive binder of avb3 and
a5b1 integrins.
12 Human glioblastoma and melanoma cells were in-
fected with MV-CKPint virus at an MOI of 1 in the absence and pres-
ence of 1 mM soluble echistatin. As shown in Figure 5, echistatin
significantly decreased killing of both cell lines by the MV-CKPint vi-
rus as a result of inhibition of cellular infection. However, inhibitionMolecular Therapy: Oncolytics Vol. 7 December 2017 59
Figure 3. MV-CKPint Infects and Kills Tumor Cells in a Dose-Dependent Manner
(A–E) Human glioblastoma (A), DIPG (B), medulloblastoma (C) and melanoma (E), and Vero (D) cell lines (shown above the graph) were infected with the retargeted virus at
increasing MOIs, and the number of live cells was counted 96 hr post-infection using the trypan blue exclusion method. (F) A comparison of killing of cell lines with the
retargeted virus (MV-CKPint) and the parental Edmonston strain of virus (MV-GFP) at an MOI of 1 for 3 hr at 37C. The number of live cells was counted after 96 hr using the
trypan blue exclusion method. The graphs represent data from at least three independent experiments, and the error bars show SEM. *p < 0.05.
Molecular Therapy: Oncolyticswas not complete. Because echistatin and CKP in the virus compete to
bind the same target integrins, a partial infection of cells with the virus
may not be completely eliminated. In addition, echistatin has been
shown to strongly bind and antagonize avb3 and a5b1 integrins,
13,14
but its interaction with avb5 integrin, which is also a target of the CKP
used in the MV-CKPint virus, is not well-known. This suggests that
the retargeted virus utilizes CKP-mediated binding with target integ-
rins for cellular entry.
To confirm integrin-binding-mediated cellular entry of the virus via
CKP, we removed the CKP motif from the viral H protein using
the activated factor X (FXa) protease cleavage site present right before
the CKP sequence in the viral H protein (Figure 1A). Pre-incubation
of virus with FXa protease markedly abrogated cell killing in dose-
dependent manner (Figure 6). Proteolytic removal of the CKPmoiety
resulted in amore than 4-fold decrease in virus infectivity, thereby cell
killing in U87 and MDAMB-435 cells, and a more than 2-fold
decrease in Vero cells at 200 mg/mL FXa. Inhibition of viral infection
was clearly demonstrated but was incomplete. This could be because
CKP moiety was not completely removed by FXa even at 200 mg/mL.
These results confirm that the integrin-binding CKPmotif is required
for cell binding and entry of the MV-CKPint virus.60 Molecular Therapy: Oncolytics Vol. 7 December 2017MV-CKPint Reaches Tumor Sites and Forms Syncytia after
Intravenous Delivery
We have established that MV-CKPint infects, replicates in, and kills
U87-MG glioblastoma tumor cells in vitro. To investigate intrave-
nous (i.v.) delivery of this modified virus, we injected mice bearing
subcutaneous U87-MG glioblastoma tumors with a single dose of
MV-CKPint (0.5  106 TCID50 [50% tissue culture infective
dose]/100 mL) or an equal volume of PBS (control) via the tail
vein. Additional control mice were injected directly into the tumor
with the same dose of MV-CKPint. Eight days post-injection,
tumors were harvested and analyzed for the presence of MV by
immunohistochemistry. In tumors from mice receiving i.v. injection
of MV-CKPint, multiple scattered small syncytia were noticed;
two representative regions of infection (foci 1 and 2) are shown
in Figure 7. The syncytia stained positive for MV nucleoprotein,
indicating for the presence of MV. For intratumoral injection, a
large but localized region of MV nucleoprotein-positive syncytia
was observed at the injection site. Additional sections from same
tumors used for immunohistochemistry were also examined by
immunofluorescence staining to confirm the presence of MV (Fig-
ure 7). This indicates that MV-CKPint virus successfully reached
the tumor bed after i.v. injection.
Figure 4. MV-CKPint Replicates in Tumor Cells
Human glioblastoma (U87), melanoma (MDAMB-435), and Vero cells were infected with the recombinant virus at an MOI of 0.2 for 3 hr. After removing the unbound virus,
cells were incubated to grow for 96 hr post-infection. (A) The intensity of GFP florescence in live cells that represents the cellular viral load was determined by flow cytometry.
The percentages of cells positive for GFP fluorescence are shown in parentheses (% +ve). (B) Cells were infected with MV-CKPint virus at an MOI of 0.2 for 3 hr at 37C. The
cell-associated virus was harvested at intervals of 24 hr, cleared from cellular components, and the titer of infectious virus particles was determined by TCID50 quantitation
assay. (C) A comparison of replication efficiency of the retargeted virus (MV-CKPint) and the parental Edmonston strain of virus (MV-GFP) in U87MGhuman glioblastoma cells
infected with virus at an MOI of 0.1 for 3 hr at 37C. The titer of the infectious virus particles was determined by TCID50 quantitation assay. Average of 3 replicates. Error bars
show SEM.
www.moleculartherapy.orgDISCUSSION
In this paper, we have described a novel approach to manufacture a
retargeted MV. We used a CKP that specifically and tightly binds
to the relatively tumor-specific integrins avb3, avb5, and a5b1 to
direct virus binding to tumor cells.11 We used a well-described
“double-blind” virus system that abrogates binding by the virus
H protein to its normal receptors to assure that the CKP was, in
fact, responsible for binding of the virus to the cell. We show
that cell killing by this retargeted MV-CKPint virus was compara-
ble to that of the parental CD46-targeting Edmonston strain of
MV on five different cell lines. Also, the retargeted virus efficiently
replicated in U87 cells, suggesting that conjugation with a CKP
does not have an adverse effect on the virus. We have demon-
strated that echistatin, a competitive binder of the integrins, abro-
gates infection by the virus, and that proteolytic cleavage of the
CKP motif from the viral H protein also prevents infection and
killing of cells. Thus, we have shown in two different ways that
MV-CKPint uses the specific binding of the CKP for cell binding
and entry.In the treatment of solid tumors, MV has required intratumoral injec-
tion for efficacy.5 Indeed, both the GBM and the medulloblastoma
phase 1 trials for solid tumor recurrence use direct injection of the tu-
mor resection bed for virus delivery. Because the avb3, avb5, and a5b1
integrins targeted by the CKP used here have been shown to be ex-
pressed by tumor vascular endothelium, the use of this CKP may
allow for effective therapy with i.v. injection of virus.15,16 To examine
this possibility, we injected animals bearing flank tumors with a single
dose of 5  105 TCID50 of MV-CKPint i.v. and harvested tumors for
analysis at 8 days after injection. A localized large area of syncytia was
observed in intratumoral-treated tumors compared to multiple small
foci of infection with intravascular virus delivery. The successful de-
livery of MV-CKPint in xenograft tumors upon i.v. injection raises
the possibility that the virus is infecting and replicating in tumor
vascular endothelium, and the resultant virus is then spreading to
the tumor cells. Further experimentation to compare the efficacy of
treatment of solid tumors both in the flank and in the brain will be
needed to determine the method of viral spread and overall efficacy
of i.v. therapy.Molecular Therapy: Oncolytics Vol. 7 December 2017 61
Figure 5. Echistatin Competitively Inhibits Infection
by MV-CKPint Virus
Human glioblastoma and melanoma cells were incubated
with the virus in the absence and presence of 1 mMsoluble
Echistatin (Ech) for 3 hr at 37C. Number of live cells was
quantified 96 hr post-infection using the trypan blue
exclusion method. The data represent three independent
experiments. Error bars indicate SEM. *p < 0.05.
Molecular Therapy: OncolyticsAn oncolytic adenovirus (Ad5) and MV have been engineered to ex-
press integrin-binding RGD motif on its glycoproteins.17–19 The
modified virus demonstrated localization in vascular endothelial cells
and slightly improved antitumor activity.20,21
One of the advantages of MV in this regard is a relative receptor
threshold effect. The more surface receptor present on a cell, the
more efficacious the MV infection.22 Indeed, there is a threshold
below which productive infection does not occur. This effect is impor-
tant with regard to integrins.While the avb3, avb5, and a5b1 integrins
have been described as tumor specific, low levels of expression on
normal cell types such as dendritic cells, T lymphocytes, vascular
smooth muscle cells, and bone have been reported.23–27 However,
this may have no effect of MV toxicity, as the receptor expression
of these normal cells may be too low to support productive infection.
This is analogous to the situation with the CD46 receptor used by cur-
rent oncolytic MVs. This protein, an inhibitor of complement-medi-
ated lysis, is expressed at below MV threshold levels by many normal
cell types, but is highly overexpressed, for obvious reasons, by most
tumor cell types.28,29
CKPs have been used to detect and monitor tumors of various types.
In fact, the CKP used here has been labeled with radio-iodine
and shown to specifically label medulloblastoma cells in a murine
model.30 Similarly, chlorotoxin, a CKP isolated from scorpion venom,
has been conjugated to a fluorescent marker to label tumors in vivo.31
This conjugate, called Tumor Paint, may allow for pre-resection label-
ing of tumor and intra-operative detection of small amounts of resid-
ual tumor, leading to a more complete tumor removal.32
Indeed, the simplicity of CKP structure lends itself to the creation of
CKP libraries. Such libraries could then be screened to identify a CKP
that binds with high affinity to a target of choice. The selected CKP
could then easily be incorporated into MV to direct infection by
the virus.33
One issue with the use of CKP for virus targeting is the requirement
for correct peptide folding and correct formation of the disulfide
bonds in the CPK for binding activity. It appears that passage of
the viral protein containing the CKP through an infected cell’s endo-
plasmic reticulum provides the proper environment to assure proper
folding and bond formation of the CKP.34,35 Passage of the viral pro-62 Molecular Therapy: Oncolytics Vol. 7 December 2017tein through the endoplasmic reticulum (ER) occurs with most envel-
oped viruses. Currently, many enveloped viruses, including herpes
simplex virus, Newcastle disease virus, and vesicular stomatitis virus,
are used both for oncolysis and as gene therapy vectors.36 The results
presented here provide proof of principle for the use of a CKP of
interest to retarget any enveloped virus for both oncolytic and gene
therapy purposes.
MATERIALS AND METHODS
Cell Culture
The human embryonic kidney cells (HEK293T), green monkey kid-
ney cells (Vero), human glioblastoma (U87MG), diffuse intrinsic
pontine glioma (DIPG-SF8628), melanoma (MDAMB-435), and me-
dulloblastoma (DAOY, D283-med) cell lines were cultured in DMEM
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/
streptomycin, and 2 mM L-glutamine and maintained at 37C in
a humidified incubator set at 5% CO2. The authentication of all hu-
man cell lines was confirmed by short tandem repeat (STR) DNA
profiling technique (DNA sequencing facility, UC Berkeley, Berkeley,
CA, USA).
Preparation and Rescue of MV-CKPint
The cDNA of the integrin-specific CKP (EETI 2.5F) was commer-
cially synthesized at Genscript (Piscataway, NJ, USA) using the amino
acid sequence 50-GCPRPRGDNPPLTCKQDSDCLAGCVCGPNG
FCG-30.11 The sequence was flanked with 50-Sfi1 and 30-Not1 restric-
tion sites, and the enzyme-digested fragment was inserted in-frame at
the C terminus of the MV H gene in the shuttle vector pTNH6aa.37
The H gene in this vector contains two point mutations resulting in
the substitutions Y481A and R533A, which eliminates binding of
the H protein to its normal receptors, CD46 and SLAM, respectively.
After cloning the CKP, the entire H gene was isolated from pTNH6aa
after digesting with Pac1 and Spe1 restriction enzymes, and ligated
into the corresponding sites in the p(+)MV-EGFP vector that codes
for all six genes of MV. The viral plasmid was amplified by trans-
forming One Shot Top10 competent cells (Life Technologies, Carls-
bad, CA, USA) and purified using the plasmid maxi prep kit from
QIAGEN (Valencia, CA, USA). The resulting MV-CKPint virus
was prepared by transfecting HEK293T cells with the recombinant
p(+)MV-EGFP-CKP vector along with packaging plasmids using
the FuGENE HD transfection reagent (Promega, Madison, WI,
USA). For robust preparation of MV-CKPint stocks, we used
Figure 6. Proteolytic Removal of the CKP Prevents
Infection by MV-CKPint Virus
MV-CKPint was treated with FXa protease at 100 and
200 mg/mL for 2 hr. Untreated and protease-treated virus
was used to infect human glioblastoma (U87), melanoma
(MDAMB-435) and vero cells for 3 hr at 37C. The number
of live cells was quantified 96 hr post-infection using the
trypan blue exclusion method (bar graphs). The experi-
ments were performed in three independent repeats.
Error bars represent SEM. *p < 0.05. The degree of CKP
removal by the protease was determined by western
blotting of the MV-CKPint lysate using antibody against
the 6xHis-tag, which is expressed after the CKPmotif. MV
nucleoprotein (N protein) was used as the control for
loading.
www.moleculartherapy.orgVero-aHis cells. These cells are modified to express membrane-
bound single-chain antibodies for anti-hexahistidine that allows
cellular entry of this blind virus due to the 6xHis-tag attached to
the H protein after the CKP sequence, as described before.37 Cells
were scraped from plates in minimal volume of Opti-MEM media,
lysed to release virus by two cycles of freeze-thaw in liquid nitrogen,
and centrifuged at 10,000  g for 5 min to clarify virus stock from
cellular debris. The aliquots of supernatant-containing virus were
stored at80C, and the titer was determined as TCID50 by infecting
aHis Vero cells in serial dilutions as described previously.38
In Vitro Cell Killing, Cytopathic Effect, and Virus Replication
One hundred thousand tumor cells per well were seeded in 12-well
plates. The next day, cells were infected with MV-CKPint at different
MOIs in 0.5 mL of Opti-MEM media for 3 hr at 37C. Control wells
were incubated in Opti-MEM only. The virus was removed and cells
were maintained in the growth medium. After 96 hr, the number of
live cells was determined by the trypan blue exclusion method and
counted using Countess, the automated cell counting instrument
(Thermo Fisher Scientific, Carlsbad, CA, USA). The percent survival
from each treatment was calculated by dividing the number of viable
cells in the infected well by the average of viable cells in control wells.
The MV-CKPint virus expresses the EGFP, hence the infection of
cells and formation of syncytia were confirmed by fluorescence mi-
croscopy. To examine the replication efficiency of the virus, we seeded
2 105 U87 andMDAMB-435 cells per well in a six-well format plate
and infected them withMV-CKPint virus at anMOI of 0.2 for 3 hr on
rocker at 37C. To compare the replication of retargeted MV-CKPint
virus with the parental Edmonston vaccine strain of MV (MV-GFP),
we infected U87 cells (2  105 per well) in six-well plates in parallel
with MV-CKPint virus and MV-GFP virus at an MOI of 0.1 for
3 hr on rocker at 37C. The incubator temperature was kept at
37C for the first 48 hr and then decreased to 32C until 96 hrMolecular Tpost-infection, to avoid rupturing of syncytia
to maximize collection of cell-associated virus.
At 24, 48, 72, and 96 hr post-infection, superna-
tant was removed, and cells were scraped from
the dish and lysed with two rounds of freeze-thaw in liquid nitrogen to harvest cell-associated virus particles. After
centrifugation at 5,000 g for 5 min to remove cell debris, the super-
natant was immediately used in the serial dilution assay on aHis Vero
cells or Vero cells to quantify the titer of MV-CKP-int and MV-GFP
virus, respectively.
Flow Cytometry
The expression of avb3, avb5, and a5b1 integrin dimers on cell surface
was analyzed by fluorescence-activated cell sorting (FACS) analysis
on live cells. Cells were removed from the dish with TrypLE (GIBCO,
Grand Island, NY, USA), centrifuged in cold media, and the pellet
was washed with cold flow cytometry (FC) buffer (PBS containing
0.1% sodium azide and 2 mM EDTA). Cells were incubated with
phycoerythrin-conjugated primary antibodies for avb3 (EMD Milli-
pore, Temecula, CA, USA), avb5 (R&D, Minneapolis, MN, USA),
and the IgG-isotype control (eBioscience, San Diego, CA, USA).
Unconjugated antibody was used for staining a5b1 integrin (EMD
Millipore). All primary antibodies were incubated for 1 hr at 4C.
Alexa Fluor 594-conjugated secondary antibody for 30 min at 4C
was used for a5b1 integrin. After antibody incubations, cells were
washed three times with FC buffer, and live cells were analyzed on
the BD FACSCalibur using the Cell Quest software.
Competitive Binding Assay and FXa Cleavage of MV-CKPint
U87MG glioblastoma and MDAMB-435 melanoma cells were seeded
at 105 cells per well in 12-well plates. Cells were washed with PBS and
incubated with MV-CKPint at an MOI of 1 in the absence and pres-
ence of 1 mM echistatin in Opti-MEM medium for 3 hr on rocker at
37C. The supernatant containing unbound virus and echistatin was
removed, and cells were grown in 10% FBS media. For the FXa pro-
teolysis assay, prior to cellular infection, the number of MV-CKPint
virus equivalent to an MOI of 1 was incubated with FXa protease
(New England Biolabs, Ipswich, MA, USA) at final concentrationsherapy: Oncolytics Vol. 7 December 2017 63
Figure 7. MV-CKPint Virus Infects Subcutaneous
U87 Glioblastoma Tumor after Intravenous Delivery
Mice containing flank tumor were given 5  105 TCID50
MV-CKPint virus intravenously (i.v.) via tail vein injection.
Intratumoral injection of the same dose was used as the
positive control of infection. After 8 days, tumors were
harvested and processed to detect measles virus nucle-
oprotein by immunohistochemistry (IHC) and immunoflu-
orescence (red channel). Two representative foci of
infection from i.v.-treated tumors (foci 1 and 2) and one
for the IT injection are shown. Formation of syncytia
and positive MV nucleoprotein reactivity in perinuclear
cytoplasmic space (merge panel) was detected in both
routes of delivery. Original magnification 400. Scale
bars, 20 mm.
Molecular Therapy: Oncolyticsof 100 and 200 mg/mL in Opti-MEM media. The virus was incubated
with FXa at room temperature for 1 hr and then for an additional 1 hr
at 37C in the water bath. The untreated and FXa-treated virus was
added to cells for 3 hr at 37C on a rocker in the 5% CO2 incubator.
The unbound virus was removed, and cells were grown in 10% FBS
media. At 96 hr post-infection, the number of live cells was counted
with the Countess using the trypan blue method.
In Vivo Model and Immunohistochemistry
All animal procedures were approved and performed according to the
University of California, San Francisco (UCSF) Institutional Animal
Care and Use Committee (IACUC) guidelines. Human U87 glioblas-
toma cells (1  106 in 100 mL) were injected subcutaneously in the
right flank of 6-week-old NOD-SCID IL2Rgnull (NSG)-immunodefi-
cient mice. At an approximate tumor diameter of 1 cm, mice were in-
jected i.v. with 5 105 TCID50 of MV-CKPint virus diluted in 100 mL
of PBS by the tail vein. Two mice were also injected with the virus by
intratumoral injection and used as the positive control for immuno-
histochemistry analysis. After 8 days of virus injection, tumors were
harvested after cardiac perfusion of animals with PBS and fixed in
10% neutral-buffered formalin for 24 hr at 4C followed by storage
at 4C in 70% ethanol. Tissues were paraffin-embedded; then 5 mm
sections were affixed on charged slides. For immunohistochemistry,
sections were deparaffinized in xylene and then hydrated by running
through graded ethanol (100%, 90%, 70%, and 50%) solutions. Sec-64 Molecular Therapy: Oncolytics Vol. 7 December 2017tions were subjected to heat-induced antigen
retrieval in sodium citrate buffer (pH 6.0) by
cooking in a pressure cooker for 35 min. After
gradual cooling at room temperature for
20 min, slides were washed with distilled water.
Incubation in 3% H2O2 solution was performed
for 20 min to block the endogenous peroxidase
activity. After washing with TBST (Tris-buff-
ered saline solution containing 0.2% Tween
20), tissue sections were encircled with an
immunohistochemistry PAP pen (Enzo Life Sci-
ences, NY, USA) and incubated in a protein su-
per block solution for 15 min (ScyTek Labora-tories, UT, USA) at room temperature. Slides were incubated with
biotin-blocking solutions A and B for 15 min each (ScyTek Labora-
tories). After washing with TBST, tissue sections were incubated
with the anti-measles nucleoprotein primary antibody (NB100-
1856; Novus Biologicals, CO, USA) at a 1:200 dilution for 2 hr at
room temperature. To assure specific binding of the anti-measles
antibody, we used an IgG-isotype control side by side from the
same species as the primary antibody. Then, slides were incubated
with the ready-to-use UltraTek Anti-Polyvalent Biotinylated second-
ary antibody (ScyTek Laboratories) for 30 min. Then, sections were
incubated in UltraTek streptavidin-conjugated HRP solution (ScyTek
Laboratories) for 15 min. Then, TBST-washed slides were incubated
with the diaminobenzidine (DAB) substrate (ScyTek Laboratories)
for 2 min and washed with tap water. Sections were counterstained
with hematoxylin for 5 min and blued using Scott’s water. Slides
were washed with running tap water and dehydrated in increasing
ethanol concentrations followed by rinsing in xylene. A coverslip
was mounted over tissue sections using the Cytoseal-60 mounting
medium (Thermo Fisher Scientific, MI, USA). One section from
each mouse was used for H&E staining. For immunofluorescence, af-
ter antigen retrieval, tumor sections were treated for 5 min with 0.5%
Triton X-100 and then blocked for 60 min in buffer containing 5%
normal goat serum, 2% bovine serum albumin, and 0.1% Tween 20
dissolved in PBS. Slides were incubated with the primary antibody
for 2 hr followed by 1 hr incubation with the secondary antibody at
www.moleculartherapy.orgroom temperature. After three washes with TBST, a coverslip was
mounted with ProLong Gold antifade media containing DAPI (Mo-
lecular Probes, Thermo Fisher Scientific, OR, USA). The immunohis-
tochemistry and immunofluorescence staining images were captured
with the monochrome camera (400 magnification) using the Zeiss
Axio Imager.A2 microscope. The merge channel images in Figure 7
were created using the ImageJ software from the NIH.
Statistical Analysis
Experiments were performed at least three times with three replicates
per group of treatment. Statistical analysis was performed with
Microsoft Office Excel using Student’s paired t test, and the level of
significance was set at p < 0.05.
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